The MINDACT trial: The first prospective clinical validation of a genomic tool

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Molecular Oncology

• Publication date

  2007-12-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.molonc.2007.10.004PMID 19383299PMCID PMC5543876
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Predicting protein-protein interactions in Arabidopsis thaliana through integration of orthology, gene ontology and co-expression

  2009cited by this paper
• Clinical application of the 70-gene profile: the MINDACT trial.

  2008cited by this paper
• Individualization of therapy using Mammaprint: from development to the MINDACT Trial.

  2007influential reference
• The MINDACT trial: The first prospective clinical validation of a genomic tool

  2007cited by this paper
• Robust interlaboratory reproducibility of a gene expression signature measurement consistent with the needs of a new generation of diagnostic tools

  2007cited by this paper
• Strong Time Dependence of the 76-Gene Prognostic Signature for Node-Negative Breast Cancer Patients in the TRANSBIG Multicenter Independent Validation Series

  2007cited by this paper
• Cancer Genomics & Proteomics

  2007cited by this paper
• Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis.

  2006cited by this paper
• Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial

  2006influential reference
• Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer.

  2006cited by this paper
• Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer.

  2006cited by this paper
• Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer.

  2005cited by this paper
• Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.

  2005cited by this paper
• A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.

  2004cited by this paper
• Repeated observation of breast tumor subtypes in independent gene expression data sets

  2003cited by this paper
• Breast cancer classification and prognosis based on gene expression profiles from a population-based study

  2003cited by this paper
• Meeting highlights: International Consensus Panel on the treatment of primary breast cancer.

  2002cited by this paper
• Gene expression profiling predicts clinical outcome of breast cancer

  2002cited by this paper
• A gene-expression signature as a predictor of survival in breast cancer.

  2002cited by this paper
• Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

  2001cited by this paper
• Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer.

  2001cited by this paper
• Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer.

  2001cited by this paper
• Molecular portraits of human breast tumours

  2000cited by this paper
• A Final Comment

  1985cited by this paper

• Real‐World Molecular Analyses May Overestimate Chemotherapy Benefit in HR‐Positive/HER2‐Negative Breast Cancer

  2026cites this paper
• Prognostic and predictive performance of PREDICT 2.1, PREDICT v3, and RSClin in node-negative early breast cancer: a TEAM pathology substudy

  2026influential citation
• Mapping metastatic potential through cytoskeletal remodeling: A mechanobiology-based multi-cancer analysis.

  2026cites this paper
• Using Artificial Intelligence to Develop Clinical Decision Support Systems—The Evolving Road of Personalized Oncologic Therapy

  2025cites this paper
• Development and validation of AI-driven multi-omics language models for cancer genomics: A comprehensive review

  2025cites this paper
• Prognostication and treatment predictions for estrogen receptor positive early-stage breast cancer: incorporating the 70-gene signature into the PREDICT prognostication model

  2025cites this paper
• Clinicopathologic and molecular characterization of low-grade, early-stage, and HER2-positive invasive breast carcinoma.

  2025cites this paper
• Decoding RNA Therapeutics: Precision Approaches in Women's Health.

  2025cites this paper
• Physician treatment decisions for hormone receptor-positive, HER2-negative early breast cancer in young patients: a Latin American survey

  2025cites this paper
• NCAPH drives breast cancer progression and identifies a gene signature that predicts luminal a tumour recurrence

  2024cites this paper
• Enhancing clinical decision support with genomic tools in breast cancer: A Scottish perspective

  2024cites this paper
• The variability of aggressiveness of grade 1 breast cancer.

  2023cites this paper
• Blood-Based mRNA Tests as Emerging Diagnostic Tools for Personalised Medicine in Breast Cancer

  2023cites this paper
• NCAPH Drives Breast Cancer Progression and Identifies a Gene Signature that Predicts Luminal A Tumor Recurrence

  2023cites this paper
• Using MammaPrint on core needle biopsy to guide the need for axillary staging during breast surgery.

  2023cites this paper
• Gene expression profiles in clinically T1-2N0 ER+HER2− breast cancer patients treated with breast-conserving therapy: their added value in case sentinel lymph node biopsy is not performed

  2023cites this paper
• Deciphering Phenotypes from Protein Biomarkers for Translational Research with PIPER.

  2023cites this paper
• Construction of a lncRNA-mediated ceRNA network and a genomic-clinicopathologic nomogram to predict survival for breast cancer patients

  2022cites this paper
• Anesthetics and Long Term Cancer Outcomes: May Epigenetics Be the Key for Pancreatic Cancer?

  2022cites this paper
• Precision diagnostics in cancer: Predict, prevent, and personalize.

  2022cites this paper
• Diagnostic Trials

  2021cites this paper
• Current Achievements and Applications of Transcriptomics in Personalized Cancer Medicine

  2021cites this paper
• A Novel Three-Gene Score as a Predictive Biomarker for Pathologically Complete Response after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer

  2021cites this paper
• Solving current dilemmas in the adjuvant endocrine treatment of pre- and perimenopausal women with an estrogen receptor positive breast cancer

  2021cites this paper
• Prediction of Breast Cancer Recurrence Using a Deep Convolutional Neural Network Without Region-of-Interest Labeling

  2021cites this paper
• The Role of Multigene Assays in Adjuvant Treatment Decision for Early-Stage Breast

  2020cites this paper
• Validation of the revised 8th AJCC breast cancer clinical prognostic staging system: analysis of 5321 cases from a single institution

  2020cites this paper
• The Potential Use of Tumour-Based Prognostic and Predictive Tools in Older Women with Primary Breast Cancer: A Narrative Review

  2020cites this paper
• Adjuvant Systemic Chemotherapy for HER2-Negative Disease

  2019cites this paper
• Next Generation Sequencing (NGS): A Revolutionary Technology in Pharmacogenomics and Personalized Medicine in Cancer.

  2019cites this paper
• Research-based PAM50 signature and long-term breast cancer survival

  2019cites this paper
• Panoptic View of Prognostic Models for Personalized Breast Cancer Management

  2019cites this paper
• Genetic Panels in Breast Cancer: Current Guidelines

  2019cites this paper
• Pathology Meets Biology: the New Era of Breast Cancer Staging

  2019cites this paper
• Translational Research and Onco-Omics Applications in the Era of Cancer Personal Genomics

  2019cites this paper
• Consenso Mexicano sobre diagnóstico y tratamiento del cáncer mamario. Octava revisión. Colima 2019

  2019cites this paper
• Molecular determinants of post-mastectomy breast cancer recurrence

  2018cites this paper
• High-throughput molecular techniques and personalized treatment for primary breast cancer

  2018cites this paper
• Molecular Prognostic Factors for Breast Carcinoma

  2018cites this paper
• Clinical and molecular aspects of breast cancer: Targets and therapies.

  2018cites this paper
• Identification of risk in cutaneous melanoma patients: Prognostic and predictive markers

  2018cites this paper
• Infiltrating Carcinomas of the Breast: Not One Disease

  2018cites this paper
• Molecular Genomic Testing for Breast Cancer: Utility for Surgeons

  2018cites this paper
• Prognostic and Predictive Factors in Breast Carcinoma

  2018cites this paper
• Extended Adjuvant Endocrine Therapy in Breast Cancer: Evidence and Update — A Review

  2017influential citation
• The Evolution of Oncology Companion Diagnostics from Signal Transduction to Immuno-Oncology.

  2017cites this paper
• Beyond Correlations, Sensitivities, and Specificities: Case Examples of the Evaluation of Advanced Imaging in Oncology Clinical Trials and Cancer Treatment.

  2017cites this paper
• Cancer as a Paradigm for Translational and Clinical Biomedical Research

  2017cites this paper
• The Era of Multigene Panels Comes? The Clinical Utility of Oncotype DX and MammaPrint

  2017cites this paper
• Beyond Correlations, Sensitivities, and Specificities: A Roadmap for Demonstrating Utility of Advanced Imaging in Oncology Treatment and Clinical Trial Design.

  2017cites this paper
• IHC 4 score plus clinical treatment score predicts locoregional recurrence in early breast cancer

  2016cites this paper
• News on the medical treatment of young women with early-stage HER2-negative breast cancer

  2016cites this paper
• Equivalence of MammaPrint array types in clinical trials and diagnostics

  2016cites this paper
• IHC4 score plus clinical treatment score predicts locoregional recurrence in early breast cancer.

  2016cites this paper
• Use of maintenance endocrine therapy after chemotherapy in metastatic breast cancer.

  2016cites this paper
• Validation of Prognostic Marker Tests: Statistical Lessons Learned From Regulatory Experience

  2016cites this paper
• Prognostic factors in breast cancer with focus on proliferation and non-linear effects

  2016influential citation
• Evaluación del perfil hormonal en pacientes con cáncer de mama precoz sometidas a hormonoterapia adyuvante

  2016cites this paper
• Intégration des facteurs prédictifs de l'effet d'un traitement dans la conception et l'analyse des essais cliniques de petite taille : application à la maladie de Huntington.

  2016cites this paper
• Identification and Construction of Combinatory Cancer Hallmark-Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal Cancer.

  2016cites this paper
• 119788_Carina Forsare

  2016influential citation
• Gene expression profiling of circulating tumor cells in breast cancer.

  2015cites this paper
• Statistical learning methods for multi-omics data integration in dimension reduction, supervised and unsupervised machine learning

  2015cites this paper
• Prospective Validation of a 21-Gene Expression Assay in Breast Cancer.

  2015cites this paper
• miR-30e* is an independent subtype-specific prognostic marker in breast cancer

  2015cites this paper
• Extended adjuvant endocrine therapy in hormone-receptor positive early breast cancer: current and future evidence.

  2015cites this paper
• Prognostic relevance of biological subtype overrides that of TNM staging in breast cancer: discordance between stage and biology

  2015cites this paper
• Identifying patients at high risk of breast cancer recurrence: strategies to improve patient outcomes

  2015cites this paper
• Development and Validation of a Nomogram to Predict Pathological Complete Response to Neoadjuvant Chemotherapy for Breast Cancer

  2015cites this paper
• Implicaciones pronósticas y terapéuticas del receptor del factor de crecimiento fibroblástico en pacientes con cáncer de mama metastásico

  2015cites this paper
• Subtype-Speci fi c Metagene-Based Prediction of Outcome after Neoadjuvant and Adjuvant Treatment in Breast Cancer

  2015cites this paper
• Placental transcriptome in development and pathology: expression, function, and methods of analysis.

  2015cites this paper
• Intra-Tumour Signalling Entropy Determines Clinical Outcome in Breast and Lung Cancer

  2015cites this paper
• Predictive markers in breast cancer: An update on ER and HER2 testing and reporting.

  2015cites this paper
• Progress in adjuvant chemotherapy for breast cancer: an overview

  2015cites this paper
• RUV for normalization of expression array data

  2015cites this paper
• S 1 Text : Intra-tumour signalling entropy determines clinical outcome in breast and lung cancer

  2015cites this paper
• Subtype-Specific Metagene-Based Prediction of Outcome after Neoadjuvant and Adjuvant Treatment in Breast Cancer

  2015cites this paper
• Testing devices or experimental systems? Cancer clinical trials take the genomic turn.

  2014cites this paper
• The impact of the pathological lymph node status on adjuvant systemic treatment recommendations in clinically node negative breast cancer patients

  2014cites this paper
• Transcriptomics in Health and Disease

  2014cites this paper
• Correlation Between E-cadherin Immunoexpression and Efficacy of First Line Platinum-Based Chemotherapy in Advanced High Grade Serous Ovarian Cancer

  2014cites this paper
• Subtype‐dependent prognostic relevance of an interferon‐induced pathway metagene in node‐negative breast cancer

  2014cites this paper
• Getting the most from molecular cancer data using unsupervised feature learning

  2014cites this paper
• A risk-management approach for effective integration of biomarkers in clinical trials: perspectives of an NCI, NCRI, and EORTC working group.

  2014cites this paper
• Local therapy for breast cancer in the molecular era: relevant or relic?

  2014cites this paper
• A tumor DNA complex aberration index is an independent predictor of survival in breast and ovarian cancer

  2014cites this paper
• Personalized Health Care (PHC) in Cancer

  2014cites this paper
• Breast Cancer Genomics

  2014cites this paper
• Molecular Pathology and Diagnostics of Breast Cancer

  2014cites this paper
• Luminal B breast cancer: molecular characterization, clinical management, and future perspectives.

  2014cites this paper
• METHOD Open Access

  2014cites this paper
• A Thirteen-Gene Expression Signature Predicts Survival of Patients with Pancreatic Cancer and Identifies New Genes of Interest

  2014cites this paper
• A catalyst for change: the European cancer Patient's Bill of Rights.

  2014cites this paper
• Microarray-Based Investigations in Cancer

  2014cites this paper
• Expression Tests in Actual Clinical Practice: How Medically Useful is the Transcriptome?

  2014cites this paper
• Biomarkers in early breast cancer and beyond: who needs all those tests?

  2014cites this paper
• cancerclass: An R Package for Development and Validation of Diagnostic Tests from High-Dimensional Molecular Data

  2014cites this paper
• Modern Risk Assessment for Individualizing Treatment Concepts in Early-stage Breast Cancer.

  2013cites this paper
• MammaPrint for individualized recurrence risk assessment and treatment recommendations for early-stage breast cancer patients

  2013cites this paper